Association of ERBB4 genetic polymorphism with the risk and prognosis of non-small cell lung cancer in Chinese Han population
Authors:
- Hai-Bo BianHBHai-Bo Bian
- Xia-Zhen WangXWXia-Zhen Wang
- Liang LiuLLLiang Liu
- Ding WeiDWDing Wei
Open Access
- 14 May 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (19) , e25762
Abstract
The aim of this study was to explore the association of rs1836724 single-nucleotide polymorphism (SNP) of ERBB4 with risk and prognosis of non-small cell lung cancer (NSCLC) in the Chinese Han population. The genotype of rs1836724 SNP of ERBB4 from 258 patients with NSCLC and 200 noncancer controls were detected the TaqMan-MGB probes real-time fluorescence polymerase chain reaction. The distribution of genotype and alleles between the 2 groups was compared, and the association between clinicopathological characteristic and rs1836724 SNP was analyzed. Prognosis and influencing factors were analyzed by Kaplan-Meier and Cox regression analysis. There were significant differences in the genotype and allele distribution of ERBB4 rs1836724 between the NSCLC group and control group (P < .05). And CC genotype of rs1836724 was associated with increased risk of NSCLC in the Chinese Han population. Rs1836724 SNP was associated with TNM stage and lymph nodal metastasis (P = .001, P = .007). The median follow-up was 29 months, and the progression-free survival and overall survival of 258 NSCLC patients were 27.91% and 31.39%, respectively. Patients with GG genotype of rs1836724 had poor progression-free survival and overall survival. Rs1836724 SNP was an independent prognostic marker of NSCLC patients, CC genotype had a high risk of poor prognosis (odds ratio = 1.587, 95% confidence interval: 1.079–2.335, P = .019). In Chinese Han populations, rs1836724 SNP of ERBB4 may contribute toward the increased risk and poor prognosis of NSCLC.Keywords
Funding Information
- CSCO Qilu Cancer Research Foundation (Y-Q201802-035)
This publication has 24 references indexed in Scilit:
- Prognostic value of ERBB4 expression in patients with triple negative breast cancerBMC Cancer, 2016
- Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patientsTumor Biology, 2015
- Activating ERBB4 mutations in non-small cell lung cancerOncogene, 2015
- ERBB4 is over-expressed in human colon cancer and enhances cellular transformationCarcinogenesis, 2015
- miR-193a-3p Functions as a Tumor Suppressor in Lung Cancer by Down-regulating ERBB4Journal of Biological Chemistry, 2015
- High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian CancerInternational Journal of Gynecological Pathology, 2014
- Mechanism for activation of mutated epidermal growth factor receptors in lung cancerProceedings of the National Academy of Sciences, 2013
- A polymorphism withinErbB4is associated with risk for hepatocellular carcinoma in Chinese populationWorld Journal of Gastroenterology, 2012
- A Novel Polymorphism in the Promoter Region ofERBB4Is Associated with Breast and Colorectal Cancer RiskClinical Cancer Research, 2007
- ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti‐cancer therapyInternational Journal of Cancer, 2006